Glonghui, April 25 | AstraZeneca announced results for the first quarter of 2024. Total revenue was US$12.679 billion, up 19% year on year at a fixed exchange rate, better than market expectations of US$11.84 billion; core earnings per share were 2.06 US dollars, up 13% year on year at fixed exchange rates, and the market expected to be 1.92 US dollars; and core operating margin was 34%. Product sales revenue during the period reached US$12.177 billion, an increase of 18% over the previous year, and the gross margin of core product sales was 82%. Among them, the oncology business performed strongly, with sales of US$5.108 billion, up 26% year on year; CVRM (cardiovascular, nephrology, metabolism) business sales of US$3.06 billion, up 23% year on year. In terms of guidance, AstraZeneca reiterated its performance guidelines for FY2024, and expects total revenue and core earnings per share to grow by double digits year-on-year.